Ameriprise
IMNM icon

Ameriprise’s Immunome IMNM Stock Holding History

Ameriprise’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.83M Sell
129,515
-61,047
-32% -$1.36M ﹤0.01% 2788
2025
Q4 		$4.09M Buy
+190,562
New +$3.34M ﹤0.01% 2579
2024
Q4 		– Sell
-336,565
Closed -$4.92M – 4119
2024
Q3 		$4.92M Buy
336,565
+83,653
+33% +$1.19M ﹤0.01% 2386
2024
Q2 		$3.06M Sell
252,912
-10,957
-4% -$171K ﹤0.01% 2643
2024
Q1 		$6.51M Buy
+263,869
New +$5.35M ﹤0.01% 2162

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Ameriprise's IMNM Position: Q1 2026 in Review

Ameriprise reduced its Immunome (IMNM) stake by 32% in Q1 2026, selling an estimated $1.36M and leaving 129,515 shares worth $2.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2788.

Ameriprise first reported a position in IMNM in Q1 2024 and has held it in 5 quarters since. The position peaked at $6.51M in Q1 2024. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Ameriprise held 129,515 shares of Immunome worth $2.83M as of Q1 2026.
  • Ameriprise sold 61,047 Immunome shares in Q1 2026, an estimated $1.36M.
  • Immunome made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2788 holding.
  • Ameriprise first reported a position in Immunome in Q1 2024 and has held it in 5 quarters since.
  • Ameriprise's Immunome position peaked at $6.51M in Q1 2024.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.